Vinorelbine (Tartrate)

Drug #1100

Vinorelbine (Tartrate) is a semi-synthetic, intravenous antineoplastic (anticancer) agent, belongs to the class of vinca alkaloids. Vinorelbine (Tartrate) is a derivative of vinblastine and has structural modifications distinctly different from other vinca alkaloids. The spectrum of activity of vinorelbine is similar to either vincristine or vinblastine, however, vinorelbine may have less neurotoxicity than vincristine. Vinorelbine was approved by the FDA for treatment of advanced non-small cell lung cancer (NSCLC) December 22, 1994. its activity in breast cancer is notable but still requires further investigation. Vinorelbine (Tartrate) is used alone or in combination with other anticancer drugs in the treatment of certain cancers such as lung cancer, breast cancer, ovarian cancer.

← Previous drug Next drug →

Primary Characteristics

It belongs to Vinca Alkaloid.

It is classified in Antineoplastic Agent, Plant Derivative pharmacological group. It is also classified under Mitotic Inhibitors .

Molecular Weight: 1079.1 · Solubility in Water: >1000 mg/ml · Solubility in Alcohol: null · Non-proprietary name: Vinorelbine (Tartrate).

Molecular structure of Vinorelbine (Tartrate)

Pharmacokinetics

Distribution: Vinorelbine (Tartrate) has a volume of distribution is 25.4 - 40 l/kg.

Elimination: it is metabolised via Hepatic, renal excretion is 18 %.

Indications

Vinorelbine (Tartrate) is primarily indicated in conditions like Lung cancer.

Vinorelbine (Tartrate) is also indicated for secondary conditions like Advanced breast cancer.

Contraindications

Vinorelbine (Tartrate) is contraindicated in conditions like Bacterial infections, Bone marrow depression.

Dosage

Vinorelbine (Tartrate)'s dosage details are as follows:

Dose	Single Dose	Frequency	Route	Instructions
Adult Dosage
27.5 mg/ sq.meter	27.5 mg/ sq.meter	—	IV	Once in a Week
Paediatric Dosage (20kg)
No data.
Neonatal Dosage (3kg)
No data.

Drug Interactions

1 interaction

Always consult your physician for the change of dose regimen or an alternative drug of choice that may strictly be required.

Side Effects

Vinorelbine (Tartrate) in overdosage may give rise to further complications which include Bone marrow depression .

Warnings / Precautions

Vinorelbine should be used with caution in patients with any pre-existing liver disease, kidney disease, lung disease, breathing trouble or any allergy. Because it may cause bleeding be careful when brushing or flossing teeth. Avoid contact with people that may have colds or flu or recently received the oral polio vaccine. Vinorelbine must be handled carefully because it can irritate the skin. Vinorlbine should be avoided if possible during pregnancy or lactation. A reliable form of contraception is recommended for use during therapy with this medication.

Available Brands

Click on a strength to view available brands.

Single Ingredient

Inj

10 mg/ml 50 mg/ml

Storage Conditions

Vinorelbine (Tartrate) should be stored Inj.

Drug Classification

1.8.2 — Cytotoxic (anti-neoplastic) drugs

Manufacturers

Manufacturers of Vinorelbine (Tartrate) in Pakistan:

Atco Bio Pharma ONCOGENE